FLT3 and acute myeloid leukemia: In 8 to 27% of cases of de novo AML, TET2 mutations have been recognized.14, 15TET2 catalyzes the modification of 5-methylcytosine to 5-hydroxymethylcytosine in DNA which results in DNA methylation.16, 17Patients with TET2 mutations show worse prognosis in individuals having NPM1 and FLT3.